157 related articles for article (PubMed ID: 34519192)
61. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
62. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
63. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
64. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
[TBL] [Abstract][Full Text] [Related]
65. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
[TBL] [Abstract][Full Text] [Related]
66. Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure.
Leshem-Rubinow E; Steinvil A; Zeltser D; Berliner S; Rogowski O; Raz R; Chodick G; Shalev V
Mayo Clin Proc; 2012 Dec; 87(12):1189-95. PubMed ID: 23141116
[TBL] [Abstract][Full Text] [Related]
67. Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure.
Yoshioka K; Matsue Y; Yamaguchi T; Kitai T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Kuroda S; Matsumura A; Hirao K
Am J Cardiovasc Drugs; 2019 Dec; 19(6):597-605. PubMed ID: 31218508
[TBL] [Abstract][Full Text] [Related]
68. Differential Effects of Combination of Renin-Angiotensin-Aldosterone System Inhibitors on Central Aortic Blood Pressure: A Cross-Sectional Observational Study in Hypertensive Outpatients.
Pradhan A; Vishwakarma P; Bhandari M; Sethi R; Narain VS
Cardiovasc Ther; 2020; 2020():4349612. PubMed ID: 32983258
[TBL] [Abstract][Full Text] [Related]
69. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.
Bhandari S; Ives N; Brettell EA; Valente M; Cockwell P; Topham PS; Cleland JG; Khwaja A; El Nahas M
Nephrol Dial Transplant; 2016 Feb; 31(2):255-61. PubMed ID: 26429974
[TBL] [Abstract][Full Text] [Related]
70. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
[TBL] [Abstract][Full Text] [Related]
71. A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.
Hyman DA; Siebert VR; Birnbaum GD; Alam M; Birnbaum Y
Cardiovasc Drugs Ther; 2020 Apr; 34(2):215-221. PubMed ID: 32219664
[TBL] [Abstract][Full Text] [Related]
72. Intensity of hydration changes the role of renin-angiotensin-aldosterone system blockers in contrast-induced nephropathy risk after coronary catheterisation in patients with chronic kidney disease.
Guo XS; Wu DX; Bei WJ; Li HL; Wang K; Zhou YL; Duan CY; Chen SQ; Lian D; Li LW; Liu Y; Tan N; Chen JY
J Renin Angiotensin Aldosterone Syst; 2017; 18(2):1470320317708894. PubMed ID: 28490226
[TBL] [Abstract][Full Text] [Related]
73. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
[TBL] [Abstract][Full Text] [Related]
74. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period.
Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ
Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953
[TBL] [Abstract][Full Text] [Related]
75. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
González-Cambeiro MC; López-López A; Abu-Assi E; Raposeiras-Roubín S; Peña-Gil C; García-Acuña J; González-Juanatey R
Rev Port Cardiol; 2016 Dec; 35(12):645-653. PubMed ID: 27865680
[TBL] [Abstract][Full Text] [Related]
76. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
[TBL] [Abstract][Full Text] [Related]
77. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
[TBL] [Abstract][Full Text] [Related]
78. Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care.
Hurwitz JT; Grizzle AJ; Augustine J; Rehfeld R; Wild A; Abraham I
J Manag Care Spec Pharm; 2016 Jan; 22(1):40-8. PubMed ID: 27015050
[TBL] [Abstract][Full Text] [Related]
79. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
80. Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis.
Liu D; Wang LN; Li HX; Huang P; Qu LB; Chen FY
J Int Med Res; 2017 Apr; 45(2):383-398. PubMed ID: 28415944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
